Stock Taper
Cingulate Inc. is a clinical-stage biopharmaceutical company developing treatments for CNS and neurobiological disorders, including ADHD and anxiety, with lead candidates CTx-1301, CTx-1302, and CTx-2103.

CTx-1301, Cingulate’s lead once-daily ADHD treatment using the proprietary PTR™ platform, is in late-stage development with an FDA action date of May 31, 2026.
Overall rating: B
| PEER | PRICE | |
|---|---|---|
TVGN | $7.34 | COMPARE |
COCP | $1.13 | COMPARE |
PHIO | $1.08 | COMPARE |
INAB | $1.20 | COMPARE |
KALA | $0.51 | COMPARE |
BOLT | $3.90 | COMPARE |
EVGN | $0.54 | COMPARE |
APVO | $1.74 | COMPARE |